Journal Article Review Ppublish 36 citations
PubMed: 35104790 DOI: 10.3171/2021.11.FOCUS21586
Central nervous system injury-induced immune suppression.
Neurosurg Focus 52(2):E10
Authors: Eric A Sribnick, Phillip G Popovich, Mark W Hall
Affiliations
- 1Department of Neurosurgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus.
- 2The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus.
- 3Department of Neuroscience.
- 4Center for Brain and Spinal Cord Repair.
- 5Belford Center for Spinal Cord Injury, and.
- 6Medical Scientist Training Program, The Ohio State University, College of Medicine, Columbus; and.
- 7Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.
Abstract
Central nervous system trauma is a common cause of morbidity and mortality. Additionally, these injuries frequently occur in younger individuals, leading to lifetime expenses for patients and caregivers and the loss of opportunity for society. Despite this prevalence and multiple attempts to design a neuroprotectant, clinical trials for a pharmacological agent for the treatment of traumatic brain injury (TBI) or spinal cord injury (SCI) have provided disappointing results. Improvements in outcome from these disease processes in the past decades have been largely due to improvements in supportive care. Among the many challenges facing patients and caregivers following neurotrauma, posttraumatic nosocomial infection is a significant and potentially reversible risk factor. Multiple animal and clinical studies have provided evidence of posttraumatic systemic immune suppression, and injuries involving the CNS may be even more prone, leading to a higher risk for in-hospital infections following neurotrauma. Patients who have experienced neurotrauma with nosocomial infection have poorer recovery and higher risks of long-term morbidity and in-hospital mortality than patients without infection. As such, the etiology and reversal of postneurotrauma immune suppression is an important topic. There are multiple possible etiologies for these posttraumatic changes including the release of damage-associated molecular patterns, the activation of immunosuppressive myeloid-derived suppressor cells, and sympathetic nervous system activation. Postinjury systemic immunosuppression, particularly following neurotrauma, provides a challenge for clinicians but also an opportunity for improvement in outcome. In this review, the authors sought to outline the evidence of postinjury systemic immune suppression in both animal models and clinical research of TBI, TBI polytrauma, and SCI.
MeSH
Central Nervous System, Infections, Morbidity, Risk, Neurosurgery, Wounds And Injuries, Immunosuppression Therapy, Trauma, Nervous System, Caregivers, Hospital Mortality, Spinal Cord Injuries, Myeloid-Derived Suppressor Cells
Cited by
- Peripheral immune reactions following human traumatic spinal cord injury: the interplay of immune activation and suppression. Front Immunol, 2024
- Granulocyte-macrophage colony-stimulating factor reduces lung bacterial load following traumatic brain injury and hemorrhage polytrauma in a juvenile rat model. PLoS One, 2025
- Radiation immunodynamics in patients with glioblastoma receiving chemoradiation. Front Immunol, 2024
- Functionalized extracellular vesicles of mesenchymal stem cells for regenerative medicine. J Nanobiotechnology, 2025
- The brain-bone marrow axis and its implications for chronic traumatic brain injury. Res Sq, 2023
- Non-cellular immunotherapies in pediatric central nervous system tumors. Front Immunol, 2023
- An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas. Curr Treat Options Oncol, 2024
- Extracranial Effects of Traumatic Brain Injury: A Narrative Review. Clin Pract, 2025
- Immune Response in Traumatic Brain Injury. Curr Neurol Neurosci Rep, 2024
- Association of common infections with cognitive performance in the Baltimore Epidemiologic Catchment Area study follow-up. Alzheimers Dement, 2023
- Cellular senescence as a key contributor to secondary neurodegeneration in traumatic brain injury and stroke. Transl Neurodegener, 2024
- Serum Angiopoietin-2 level increase differs between polytraumatized patients with and without central nervous system injuries. Sci Rep, 2023
- Impact of Early-Life Brain Injury on Gut Microbiota Composition in Rodents: Systematic Review with Implications for Neurodevelopment. Cells, 2025
- Chronic Intermittent Hypoxia-Induced Neural Injury: Pathophysiology, Neurodegenerative Implications, and Therapeutic Insights. CNS Neurosci Ther, 2025
- Granulocyte- Macrophage Colony-Stimulating Factor Reverses Immunosuppression Acutely Following a Traumatic Brain Injury and Hemorrhage Polytrauma in a Juvenile Male Rat Model. J Neurotrauma, 2024
- A blunted T17 cytokine signature in women with mild cognitive impairment: insights from inflammatory profiling of a community-based cohort of older adults. Brain Commun, 2023
- Biomarker expression level changes within rectal gut-associated lymphoid tissues in spinal cord-injured rats. Immunohorizons, 2025
- High Neutrophil-to-Lymphocyte Ratio Facilitates Cancer Growth-Currently Marketed Drugs Tadalafil, Isotretinoin, Colchicine, and Omega-3 to Reduce It: The TICO Regimen. Cancers (Basel), 2022
- The effects of cytomegalovirus on brain structure following sport-related concussion. Brain, 2023
- Glioblastoma progression is hindered by melatonin-primed mesenchymal stromal cells through dynamic intracellular and extracellular reorganizations. Theranostics, 2025